Skip to main content
Premium Trial:

Request an Annual Quote

Nanogen to Acquire Syn X Pharma in CA$16.3M Transaction

NEW YORK, Feb. 10 (GenomeWeb News) - Nanogen plans to acquire Syn X Pharma in an all-stock transaction, the company said today.


The transaction is valued at approximately CA$16.3 million ($12.3 million). Under the agreement, Nanogen will offer common shares to holders of Syn X common shares in a stock-for-stock exchange.


Nanogen, based in San Diego, plans to operate Toronto-based Syn X as a business unit under its current name and retain the company's research facility. Syn X managers George Jackowski and Rod Wilson are to join Nanogen's management team. Nanogen said the acquisition will help it expand its share in the in vitro diagnostics market. The company expects the Syn X unit to be cash flow positive by the end of 2005.


The acquisition, unanimously approved by Syn X directors, is subject to Syn X shareholder approval and other conditions. Nanogen expects the deal to close by the end of June.


Click here for further information from Nanogen.


The Scan

Interfering With Invasive Mussels

The Chicago Tribune reports that researchers are studying whether RNA interference- or CRISPR-based approaches can combat invasive freshwater mussels.

Participation Analysis

A new study finds that women tend to participate less at scientific meetings but that some changes can lead to increased involvement, the Guardian reports.

Right Whales' Decline

A research study plans to use genetic analysis to gain insight into population decline among North American right whales, according to CBC.

Science Papers Tie Rare Mutations to Short Stature, Immunodeficiency; Present Single-Cell Transcriptomics Map

In Science this week: pair of mutations in one gene uncovered in brothers with short stature and immunodeficiency, and more.